Welcome to our dedicated page for Galecto SEC filings (Ticker: GLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galecto, Inc. (NASDAQ: GLTO) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures, giving investors structured access to official information about this clinical-stage biopharmaceutical issuer. Galecto files current and periodic reports with the U.S. Securities and Exchange Commission that describe its oncology and liver disease pipeline, capital structure and key corporate events.
For GLTO, Form 8-K filings are particularly important. Recent 8-Ks detail the acquisition of Damora Therapeutics and the resulting expansion into mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms, the related private placement of Series C non-voting convertible preferred stock, and the issuance of warrants under an antibody discovery and option agreement. Other 8-Ks describe executive appointments, inducement equity awards, and stockholder meeting results, providing insight into governance and leadership changes as Galecto advances DMR-001, DMR-002 and GB3226.
Annual and quarterly reports (Forms 10-K and 10-Q, when available) give more detailed views of Galecto’s research and development spending, general and administrative expenses, net losses and cash runway. These filings also summarize the status of key programs such as GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML, and GB1211, a galectin-3 inhibitor for liver cirrhosis and oncology combinations. Investors can review risk factor discussions and management’s commentary on the company’s strategic focus on cancer and liver diseases.
On this page, Stock Titan pairs Galecto’s raw SEC documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify material items such as mergers, financings, warrant issuances and preferred stock conversions. Real-time updates from EDGAR ensure new GLTO filings appear promptly, while access to insider-related disclosures, when filed on Form 4 or within other reports, can help users monitor equity grants and ownership changes involving directors and officers.
Whether you are analyzing Galecto’s evolving hematology-oncology pipeline, reviewing the terms of its private placements, or tracking its Nasdaq listing-related disclosures, this GLTO filings page offers a focused view of the company’s regulatory record with tools to make complex documents easier to understand.